NCT01816971View on ClinicalTrials.gov

Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

April 1, 2018

Study Completion Date

December 1, 2026

Conditions
Stage I Multiple MyelomaStage II Multiple MyelomaStage III Multiple Myeloma
Interventions
DRUG

dexamethasone

Given IV or PO

DRUG

carfilzomib

Given IV

DRUG

lenalidomide

Given PO

PROCEDURE

autologous hematopoietic stem cell transplantation

Undergo autologous hematopoietic stem cell transplant

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (5)

37203

Sarah Cannon Cancer Center, Nashville

63130

Washington University in St Louis, St Louis

60637-1470

University of Chicago Comprehensive Cancer Center, Chicago

02215

Dana Farber, Boston

M5T 2M9

Princess Margaret, Toronto

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Chicago

OTHER

NCT01816971 - Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | Biotech Hunter | Biotech Hunter